Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 1/20 | 0.60 |
| ▸ | MMP8 | P22894 | 1/20 | 0.60 |
| ▸ | MME | P08473 | 5/20 | 0.58 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 5/20 | 0.51 |
| ▸ | CPA1 | P15085 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12637374 | 0.91 | SIGMAR1 (0.62) | MMP9MMP8MMESIGMAR1ACE | |
| SCHEMBL12637371 | 0.91 | SIGMAR1 (0.62) | MMP9MMP8MMESIGMAR1ACE | |
| SCHEMBL1881900 | 0.91 | SIGMAR1 (0.62) | MMP9MMP8MMESIGMAR1ACE | |
| SCHEMBL8197333 | 0.91 | SIGMAR1 (0.62) | MMP9MMP8MMESIGMAR1ACE | |
| SCHEMBL1878623 | 0.91 | SIGMAR1 (0.62) | MMP9MMP8MMESIGMAR1ACE | |
| SCHEMBL6936961 | 0.85 | MMP8 (0.54) | MMP9MMP8MMEOPRM1OPRD1 | |
| SCHEMBL2987249 | 0.85 | FOLH1 (0.51) | MMP9MMP8MMEFOLH1ACE | |
| SCHEMBL29224714 | 0.84 | MME (0.58) | MMP9MMP8MMEFOLH1ACE | |
| SCHEMBL2982925 | 0.83 | FOLH1 (0.52) | MMP9MMP8MMEFOLH1ACE | |
| SCHEMBL5738141 | 0.83 | FOLH1 (0.61) | MMEFOLH1ACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256698-A1 | CATHEPSIN INHIBITORS | VIROBAY, INC. | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256698-A1 | CATHEPSIN INHIBITORS | CTSF, CTSZ, CTSV | MMP9 206/4885MMP8 103/4885MME 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.